Harvard Bioscience (HBIO) Other Operating Expenses (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Other Operating Expenses data on file, last reported at $6.2 million in Q1 2026.

• Quarterly Other Operating Expenses fell 88.59% year-over-year to $6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.7 million (down 68.23% YoY) and the FY2025 annual result came in at $71.9 million, up 147.35% from the prior year.
• Other Operating Expenses was little changed at $6.2 million in Q1 2026 per HBIO's latest filing, from $6.2 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $54.3 million in Q1 2025 and bottomed at $5.5 million in Q3 2025.
• The 5-year median for Other Operating Expenses is $7.4 million (2023), against an average of $9.8 million.
• The widest annual swing landed in 2025, when Other Operating Expenses jumped 561.38%; it then plunged 88.59% in 2026.
• Tracing HBIO's Other Operating Expenses over 5 years: stood at $7.6 million in 2022, then gained by 0.69% to $7.6 million in 2023, then decreased by 9.97% to $6.9 million in 2024, then slipped by 10.32% to $6.2 million in 2025, then advanced by 0.49% to $6.2 million in 2026.
• Per Business Quant, the three latest HBIO Other Operating Expenses figures stand at $6.2 million (Q1 2026), $6.2 million (Q4 2025), and $5.5 million (Q3 2025).

Peer Comparison